177Lu-dotatate, known for its efficacy in treating somatostatin receptor-positive neuroendocrine tumors, could potentially target both NEPC tumors and the neuroendocrine component of AMPC19, as exemplified by the confirmed SSTR5 expression in our patient. The gene discussed is SSTR5; the disease is neuroendocrine neoplasm.